UPDATED: As PDUFA looms Sanofi punts a $35M partnership

A little more than a year after Sanofi ($SNY) stepped in to sign a development deal with Pozen, the pharma giant has stepped back out just weeks ahead of a scheduled PDUFA date. Chapel Hill, NC-based Pozen ($POZN) says the pharma giant and the biotech "mutually agreed" to end the partnership to develop a pair of new-and-improved aspirins dubbed PA8140 and PA32540. Sanofi paid $15 million in cash and promised up to $20 million more in precommercialization milestones to get the deal. Pozen CEO John Plachetka said the company would consider its strategic options, noting the drug is tackling a target market with more than 20 million consumers. Investors, though, weren't too happy with today's turn of events. Pozen's shares plunged 19% in morning trading. Pozen also has commercial names in place. PA8140 will be referred to as YOSPRALA 81/40 (enteric-coated aspirin 81 mg/immediate release omeprazole 40 mg) and PA32540 (enteric-coated aspirin 325 mg/immediate release omeprazole 40 mg) will be referred to as YOSPRALA 325/40. Release

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.